Literature DB >> 1916480

Effect of protein and lactulose on the production of gamma-aminobutyric acid by faecal Escherichia coli.

H al Mardini1, B al Jumaili, C O Record, D Burke.   

Abstract

The value of lactulose treatment in hepatic encephalopathy is widely recognised but its mode of action remains controversial. Much evidence supports a role for gamma-aminobutyric acid in hepatic encephalopathy, and lactulose could alter its bacterial production in the gut. Using the rat synaptic membrane assay and gas chromatography mass spectrometry, the production of gamma-aminobutyric acid by faecal Escherichia coli, with and without the addition of albumin, haemoglobin, whole blood, and lactulose under aerobic and anaerobic conditions was determined. Using an inorganic medium, maximal gamma-aminobutyric acid production occurred after a culture period of between 25 and 50 hours. The concentration after 30 hours of aerobic culture at 37 degrees C by a single strain was mean (SEM), 101 (5) mumol/l (99% confidence intervals 87-114 mumol/l; n = 8; interassay coefficient of variation 14.7%). gamma-aminobutyric acid production was significantly increased by the addition of albumin and haemoglobin. Under anerobic conditions, it was one fifth of that produced aerobically, but the addition of albumin and haemoglobin increased production by greater than 700%. Lactulose did not significantly attenuate gamma-aminobutyric acid production under aerobic or anaerobic conditions. gamma-aminobutyric acid determined by the rat synaptic membrane assay showed a highly significant correlation (r = 0.99) with that detected by gas chromatography mass spectrometry. These data confirm that gamma-aminobutyric acid is produced by faecal E coli and that protein enhances its production considerably, and suggest that lactulose does not exert its therapeutic effect by attenuating gamma-aminobutyric acid production.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1916480      PMCID: PMC1379039          DOI: 10.1136/gut.32.9.1007

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  20 in total

1.  Lactulose detoxifies in vitro short-chain fatty acid production in colonic contents induced by blood: implications for hepatic coma.

Authors:  P B Mortensen; H S Rasmussen; K Holtug
Journal:  Gastroenterology       Date:  1988-03       Impact factor: 22.682

2.  Serum gamma-aminobutyric acid (GABA) levels in patients with hepatic encephalopathy.

Authors:  G Y Minuk; A Winder; E D Burgess; E J Sarjeant
Journal:  Hepatogastroenterology       Date:  1985-08

3.  Increased brain uptake of gamma-aminobutyric acid in a rabbit model of hepatic encephalopathy.

Authors:  M L Bassett; K D Mullen; B Scholz; J D Fenstermacher; E A Jones
Journal:  Gastroenterology       Date:  1990-03       Impact factor: 22.682

4.  Evidence for gamma-aminobutyric acid as the inhibitor of gamma-aminobutyric acid binding in the plasma of humans with liver disease and hepatic encephalopathy.

Authors:  L J Levy; J Leek; M S Losowsky
Journal:  Clin Sci (Lond)       Date:  1987-11       Impact factor: 6.124

5.  Serum levels of gamma-aminobutyric-acid-like activity in acute and chronic hepatocellular disease.

Authors:  P Ferenci; D F Schafer; G Kleinberger; J H Hoofnagle; E A Jones
Journal:  Lancet       Date:  1983-10-08       Impact factor: 79.321

6.  Lactitol versus lactulose in the treatment of chronic hepatic encephalopathy. A double-blind, randomised, cross-over study.

Authors:  M Y Morgan; K E Hawley; D Stambuk
Journal:  J Hepatol       Date:  1987-04       Impact factor: 25.083

7.  Gamma-aminobutyric acid (GABA) production by eight common bacterial pathogens.

Authors:  G Y Minuk
Journal:  Scand J Infect Dis       Date:  1986

8.  gamma-Aminobutyric acid production in small and large intestine of normal and germ-free Wistar rats. Influence of food intake and intestinal flora.

Authors:  C L van Berlo; H R de Jonge; A E van den Bogaard; H M van Eijk; M A Janssen; P B Soeters
Journal:  Gastroenterology       Date:  1987-09       Impact factor: 22.682

9.  Comparative modes of action of lactitol and lactulose in the treatment of hepatic encephalopathy.

Authors:  D H Patil; D Westaby; Y R Mahida; K R Palmer; R Rees; M L Clark; A M Dawson; D B Silk
Journal:  Gut       Date:  1987-03       Impact factor: 23.059

10.  Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy in cirrhotic patients. A randomised, cross-over study.

Authors:  M Y Morgan; M Alonso; L C Stanger
Journal:  J Hepatol       Date:  1989-03       Impact factor: 25.083

View more
  2 in total

Review 1.  Gut Dysbiosis in Animals Due to Environmental Chemical Exposures.

Authors:  Cheryl S Rosenfeld
Journal:  Front Cell Infect Microbiol       Date:  2017-09-08       Impact factor: 5.293

2.  Hydrogel Film-Immobilized Lactobacillus brevis RK03 for γ-Aminobutyric Acid Production.

Authors:  Yi-Huang Hsueh; Wen-Chang Liaw; Jen-Min Kuo; Chi-Shin Deng; Chien-Hui Wu
Journal:  Int J Mol Sci       Date:  2017-11-03       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.